Add to ORKGSmall trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. In this cohort analysis, we use linked data from Catalonia (Spain), where those aged <60 who received a first dose of ChAdOx1 could choose between ChAdOx1 and BNT162b2 for their second dose. Comparable cohorts were obtained after exact-matching 14,325/17,849 (80.3%) people receiving heterologous vaccination to 14,325/149,386 (9.6%) receiving homologous vaccination by age, sex, region, and date of second dose. Of these, 464 (3.2%) in the heterologous and 694 (4.8%) in the homologous groups developed COVID-19 between 1st June 2021 and 5th Decembe...
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the...
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects ...
[[abstract]]Coronavirus Disease 2019 (COVID‐19) pandemic, which is caused by the severe acute respir...
Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BN...
International audienceDear Editor,A recent report questioned whether one vaccine was better than ano...
Although pivotal trials with varying populations and study methods suggest higher efficacy for mRNA ...
Background: There is a small amount of immunological data on COVID-19 heterologous vaccination sched...
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health ...
Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermitten...
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the...
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects ...
[[abstract]]Coronavirus Disease 2019 (COVID‐19) pandemic, which is caused by the severe acute respir...
Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BN...
International audienceDear Editor,A recent report questioned whether one vaccine was better than ano...
Although pivotal trials with varying populations and study methods suggest higher efficacy for mRNA ...
Background: There is a small amount of immunological data on COVID-19 heterologous vaccination sched...
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health ...
Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermitten...
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the...
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects ...
[[abstract]]Coronavirus Disease 2019 (COVID‐19) pandemic, which is caused by the severe acute respir...